337 related articles for article (PubMed ID: 33493594)
1. 1α,25-Dihydroxyvitamin D
Ben-Eltriki M; Deb S; Guns EST
J Steroid Biochem Mol Biol; 2021 May; 209():105828. PubMed ID: 33493594
[TBL] [Abstract][Full Text] [Related]
2. Calcitriol and 20(S)-protopanaxadiol synergistically inhibit growth and induce apoptosis in human prostate cancer cells.
Ben-Eltriki M; Deb S; Adomat H; Tomlinson Guns ES
J Steroid Biochem Mol Biol; 2016 Apr; 158():207-219. PubMed ID: 26709138
[TBL] [Abstract][Full Text] [Related]
3. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms.
Zhao XY; Peehl DM; Navone NM; Feldman D
Endocrinology; 2000 Jul; 141(7):2548-56. PubMed ID: 10875257
[TBL] [Abstract][Full Text] [Related]
4. Antiproliferative signalling by 1,25(OH)2D3 in prostate and breast cancer is suppressed by a mechanism involving histone deacetylation.
Banwell CM; Singh R; Stewart PM; Uskokovic MR; Campbell MJ
Recent Results Cancer Res; 2003; 164():83-98. PubMed ID: 12899515
[TBL] [Abstract][Full Text] [Related]
5. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent.
Zhao XY; Ly LH; Peehl DM; Feldman D
Endocrinology; 1997 Aug; 138(8):3290-8. PubMed ID: 9231780
[TBL] [Abstract][Full Text] [Related]
6. Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells.
Zhao XY; Ly LH; Peehl DM; Feldman D
Endocrinology; 1999 Mar; 140(3):1205-12. PubMed ID: 10067845
[TBL] [Abstract][Full Text] [Related]
7. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
Chen TC; Schwartz GG; Burnstein KL; Lokeshwar BL; Holick MF
Clin Cancer Res; 2000 Mar; 6(3):901-8. PubMed ID: 10741714
[TBL] [Abstract][Full Text] [Related]
8. Ginsenoside-mediated blockade of 1α,25-dihydroxyvitamin D3 inactivation in human liver and intestine in vitro.
Deb S; Chin MY; Adomat H; Guns ES
J Steroid Biochem Mol Biol; 2014 May; 141():94-103. PubMed ID: 24486455
[TBL] [Abstract][Full Text] [Related]
9. Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity.
Ly LH; Zhao XY; Holloway L; Feldman D
Endocrinology; 1999 May; 140(5):2071-6. PubMed ID: 10218956
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of vitamin D analogs as therapeutic agents for prostate cancer.
Chen TC; Holick MF; Lokeshwar BL; Burnstein KL; Schwartz GG
Recent Results Cancer Res; 2003; 164():273-88. PubMed ID: 12899529
[TBL] [Abstract][Full Text] [Related]
11. Genistein potentiates the growth inhibitory effects of 1,25-dihydroxyvitamin D3 in DU145 human prostate cancer cells: role of the direct inhibition of CYP24 enzyme activity.
Swami S; Krishnan AV; Peehl DM; Feldman D
Mol Cell Endocrinol; 2005 Sep; 241(1-2):49-61. PubMed ID: 15955619
[TBL] [Abstract][Full Text] [Related]
12. Vitamin B12 enhances the antitumor activity of 1,25-dihydroxyvitamin D3 via activation of caspases and targeting actin cytoskeleton.
Atoum MF; Alzoughool FE; Al-Mazaydeh ZA; Rammaha MS; Tahtamouni LH
Tumour Biol; 2022; 44(1):17-35. PubMed ID: 35180142
[TBL] [Abstract][Full Text] [Related]
13. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
Skowronski RJ; Peehl DM; Feldman D
Endocrinology; 1995 Jan; 136(1):20-6. PubMed ID: 7530193
[TBL] [Abstract][Full Text] [Related]
14. The combined treatment of 1,25-dihydroxyvitamin D3 and a non-steroid anti-inflammatory drug is highly effective in suppressing prostate cancer cell line (LNCaP) growth.
Gavrilov V; Steiner M; Shany S
Anticancer Res; 2005; 25(5):3425-9. PubMed ID: 16101159
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of 19-nor-2alpha-(3-hydroxypropyl)-1alpha,25-dihydroxyvitamin D3 as a therapeutic agent for androgen-dependent prostate cancer.
Flanagan JN; Zheng S; Chiang KC; Kittaka A; Sakaki T; Nakabayashi S; Zhao X; Spanjaard RA; Persons KS; Mathieu JS; Holick MF; Chen TC
Anticancer Res; 2009 Sep; 29(9):3547-53. PubMed ID: 19667147
[TBL] [Abstract][Full Text] [Related]
16. Induction of apoptosis and inhibition of prostate and breast cancer growth by BGP-15, a new calcipotriene-derived vitamin D3 analog.
Berkovich L; Ben-Shabat S; Sintov AC
Anticancer Drugs; 2010 Jul; 21(6):609-18. PubMed ID: 20335794
[TBL] [Abstract][Full Text] [Related]
17. 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells.
Barreto AM; Schwartz GG; Woodruff R; Cramer SD
Cancer Epidemiol Biomarkers Prev; 2000 Mar; 9(3):265-70. PubMed ID: 10750664
[TBL] [Abstract][Full Text] [Related]
18. Rh2 synergistically enhances paclitaxel or mitoxantrone in prostate cancer models.
Xie X; Eberding A; Madera C; Fazli L; Jia W; Goldenberg L; Gleave M; Guns ES
J Urol; 2006 May; 175(5):1926-31. PubMed ID: 16600800
[TBL] [Abstract][Full Text] [Related]
19. The role of vitamin D in prostate cancer.
Krishnan AV; Peehl DM; Feldman D
Recent Results Cancer Res; 2003; 164():205-21. PubMed ID: 12899524
[TBL] [Abstract][Full Text] [Related]
20. Vitamin D and systemic cancer: is this relevant to malignant melanoma?
Osborne JE; Hutchinson PE
Br J Dermatol; 2002 Aug; 147(2):197-213. PubMed ID: 12174089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
